Wikipedia

User:Mr. Ibrahem/Olmesartan

< User:Mr. Ibrahem
Mr. Ibrahem/Olmesartan
Clinical data
Trade namesBenicar
Other namesOlmesartan medoxomil
AHFS/Drugs.comMonograph
MedlinePlusa603006
License data
Pregnancy
category
  • C (D if used in second or third trimester)
Routes of
administration		By mouth
Drug classAngiotensin II receptor antagonist[1]
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability26%
MetabolismLiver (cannot be removed by hemodialysis)
Elimination half-life13 hours
ExcretionKidney 40%, biliary 60%
Identifiers
  • (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate
Chemical and physical data
FormulaC29H30N6O6
Molar mass558.595 g·mol−1
3D model (JSmol)
  • CCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)C(=O)OCc5c(oc(=O)o5)C)C(C)(C)O
  • InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34) checkY
  • Key:UQGKUQLKSCSZGY-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olmesartan, sold under the trade name Benicar among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.[1] It is a reasonable initial treatment for high blood pressure.[1] It is taken by mouth.[1] Versions are available as the combination olmesartan/hydrochlorothiazide and olmesartan/amlodipine.[1]

Common side effects include dizziness, headaches, diarrhea, and back pain.[1] Serious side effects may include kidney problems, low blood pressure, and angioedema.[1] Use in pregnancy may harm the baby and use when breastfeeding is not recommended.[3] It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.[1]

It was patented in 1991 and came into medical use in 2002.[4] It is available as a generic medication.[5] A month supply in the United Kingdom costs the NHS less than 2.50 £ as of 2019.[5] In the United States the wholesale cost of this amount is less than US$5.[6] In 2017, it was the 223rd most commonly prescribed medication in the United States, with more than two million prescriptions.[7][8]

References

edit
  1. ^ a b c d e f g h i j "Olmesartan Medoxomil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 24 April 2019. Retrieved 3 March 2019.
  2. ^ Cite error: The named reference WHO2020DDD was invoked but never defined (see the help page).
  3. ^ "Olmesartan Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 30 November 2020. Retrieved 3 March 2019.
  4. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 471. ISBN 9783527607495. Archived from the original on 2019-03-01. Retrieved 2019-03-01.
  5. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 177. ISBN 9780857113382.
  6. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  7. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  8. ^ "Olmesartan Medoxomil - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Olmesartan&oldid=1233784561"